
Aarti Drugs Ltd is Rated Buy by MarketsMOJO
2026-11-20 10:10:35Aarti Drugs Ltd is rated Buy by MarketsMOJO, with this rating last updated on 04 Nov 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 20 November 2026, providing investors with the latest insights into its performance and outlook.
Read MoreAarti Drugs Gains 13.66%: 2 Key Factors Driving the Surge
2026-11-14 16:02:26Key Events This Week Nov 9: Intraday high of Rs.486.25 with a 7.73% surge Nov 11: Minor correction to Rs.491.90 (-1.68%) Nov 12: Recovery with 3.57% gain to Rs.509.45 Nov 13: New 52-week high of Rs.527.85, closing at Rs.507.55 (-0.37%) Week Open Rs.446.55 ...
Read More
Aarti Drugs Ltd is Rated Buy by MarketsMOJO
2026-11-09 10:10:22Aarti Drugs Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 04 November 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 November 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Aarti Drugs Ltd Surges 7.73% to Day's High of Rs 486.25 — Outperforms Sector by 5.76 Percentage Points
2026-11-09 09:56:35The Sensex declined 0.24% on 09 Nov 2026 while Aarti Drugs Ltd surged 7.73%, marking a standout session with a 5.76 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers. The stock touched an intraday high of Rs 486.25, rewriting the short-term narrative amid a broadly weak market backdrop.
Read MoreAarti Drugs Gains 2.49%: 3 Key Factors Driving the Week’s Momentum
2026-11-07 16:05:23Key Events This Week Nov 2: Stock surges 4.15% on strong volume Nov 3: Continued gains lift price to Rs.465.60 (+2.60%) Nov 4: Reports strong quarterly performance; technical momentum shifts bullish Nov 5: Stock dips 2.23% despite Sensex rally Nov 6: Modest recovery with 0.51% gain; closes week at Rs.446.55 Week OpenRs.435.70 ...
Read More
Aarti Drugs Ltd Reports Strong Quarterly Performance, Upgrades Financial Trend to Positive
2026-11-04 11:00:25Aarti Drugs Ltd has demonstrated a marked improvement in its financial performance for the quarter ended September 2026, prompting an upgrade in its mojo grade from Hold to Buy. The pharmaceutical company posted record quarterly revenues and profitability metrics, signalling a positive shift in its financial trend after a period of stagnation.
Read More
Aarti Drugs Ltd Technical Momentum Shifts to Bullish Amid Strong Price Gains
2026-11-04 08:03:31Aarti Drugs Ltd has witnessed a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish stance. This change is underpinned by a confluence of positive signals across key indicators such as MACD, moving averages, and Bollinger Bands, suggesting an improving price trajectory for this small-cap pharmaceutical stock.
Read MoreAarti Drugs Surges 16.50%: 3 Key Factors Driving This Week’s Rally
2026-10-31 16:04:09Key Events This Week 26 Oct: Stock opens week at ₹379.70, up 1.52% 27 Oct: Upgraded to Hold as technicals improve; closes at ₹403.40 (+6.24%) 28 Oct: Hits intraday high of ₹454 with 9.97% surge 30 Oct: Week closes at ₹435.70, down 2.95% on the day but up 16.50% for the week Week Open Rs.374.00 <div cl...
Read More
Aarti Drugs Ltd Technical Momentum Shifts Signal Mildly Bullish Outlook
2026-10-27 08:03:51Aarti Drugs Ltd has exhibited a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance, supported by mixed signals from key indicators such as MACD, RSI, and moving averages. This transition, coupled with a recent upgrade in its Mojo Grade from Sell to Hold, suggests cautious optimism for investors amid a challenging market backdrop.
Read MoreAnnouncement under Regulation 30 (LODR)-Demise
15-Nov-2026 | Source : BSEIntimation of sad demise of Promoter and Chairman Emeritus of the Company
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
10-Nov-2026 | Source : BSETranscript of Q2&H1 FY27 Earning Conference call
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
06-Nov-2026 | Source : BSEDisclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requireents) Regulations 2015
Corporate Actions
No Upcoming Board Meetings
Aarti Drugs Ltd has declared 20% dividend, ex-date: 09 Feb 26
No Splits history available
Aarti Drugs Ltd has announced 3:1 bonus issue, ex-date: 30 Sep 20
No Rights history available